NCT06471946View on ClinicalTrials.gov

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

September 1, 2029

Study Completion Date

September 1, 2030

Conditions
Higher-risk Myelodysplastic Syndromes
Interventions
DRUG

Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT

"Patients were treated by VA Conditioning Regimen Allo-HSCT:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9"

Trial Locations (1)

100048

RECRUITING

Navy General Hospital, Beijing

All Listed Sponsors
lead

Navy General Hospital, Beijing

OTHER